ERG and prostate cancer: Of the 25 fusions not identified in RNA, 13 matched the characteristic tumor type of the known fusion pair (nine of which were TMPRSS2-ERG fusions in prostate cancer) and are likely to be pathogenic but with insufficient expression to be detected in the RNA.